CCL2 and COVID-19: However, Patients infected with SARS-CoV-2 who have the TNF-α gene variant (rs1800629) are protected from developing COVID-19 moderate and severe outcomes, as well as from presenting low concentrations of some pro-inflammatory cytokines and chemokines (IL-6, CCL2, and CXCL-10).